Correction to: Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canaglifozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting
Crossref DOI link: https://doi.org/10.1007/s40258-022-00734-z
Published Online: 2022-04-20
Published Print: 2022-07
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Stafford, Sara http://orcid.org/0000-0002-1551-6208
Bech, Peter G.
Fridhammar, Adam
Miresashvili, Nino
Nilsson, Andreas
Willis, Michael
Liu, Aiden
Text and Data Mining valid from 2022-04-20
Version of Record valid from 2022-04-20
Article History
First Online: 20 April 2022